member,isexpressedby,oncosphere,Obj
significanttumorgrowthreduction,isin,EgKI-1-treatedmice,Obj
cellcycle,inducedapoptosisof,cancercells,Obj
model,showed,significanttumorgrowthreduction,Obj
model,showed,tumorgrowthreductioninmice,Obj
EgKI-1,affecting,normalcellgrowth,Obj
EgKI-1,inhibitsmigrationin,dose-dependentmanner,Obj
EgKI-1treatment,arrested,cancercellgrowth,Obj
model,showed,tumorgrowthreductioninEgKI-1-treatedmice,Obj
recombinantEgKI-1,affecting,normalcellgrowth,Obj
recombinantEgKI-1,affecting,cellgrowth,Obj
inmodel,showed,tumorgrowthreduction,Obj
EgKI-1,showspromiseas,anti-cancertherapeutic,Obj
member,isexpressedby,oncosphereofcaninetapewormEchinococcus,Obj
member,ishighlyexpressedby,oncosphere,Obj
EgKI-1,shows,promiseforfuturedevelopment,Obj
EgKI-1treatment,Furthermorearrested,cancercellgrowth,Obj
model,showed,significanttumorgrowthreductioninEgKI-1-treatedmice,Obj
cellcycle,apoptosisof,cancercells,Obj
EgKI-1treatment,disrupting,cellcycle,Obj
member,ishighlyexpressedby,oncosphereoftapewormEchinococcus,Obj
model,showed,tumorgrowthreduction,Obj
member,ishighlyexpressedby,oncosphereofcaninetapewormEchinococcus,Obj
member,isexpressedby,oncosphereoftapewormEchinococcus,Obj
co-treatment,alsoinduced,cellapoptosis,Obj
cellgrowth,significantlyinhibited,cellproliferation,Obj
cellgrowth,inhibitedcellproliferationin,additivemanner,Obj
cellcycle,treatmentof,tamoxifen,Obj
cellcycle,combinedtreatmentof,tamoxifen,Obj
combinedtreatment,suppressed,cellmigration,Obj
investigated,combinatorialanti-proliferativeeffectson,ERcancer,Obj
combinedtreatment,suppressing,transcription,Obj
combinedtreatment,blockedcellcyclein,G2/Mphase,Obj
treatment,suppressed,cellmigration,Obj
combinedtreatment,blocked,cellcycle,Obj
cells,wereexposedto,singletamoxifen,Obj
investigated,anti-proliferativeeffectsof,tamoxifen,Obj
cellproliferation,Taken,co-treatmentoftamoxifen,Obj
naringenin,inhibit,cellgrowthathigherconcentrations,Obj
cellproliferation,Takentogether,co-treatment,Obj
investigated,effectson,ERcancer,Obj
Breastcancer,second-leadingcauseof,death,Obj
investigated,anti-proliferativeeffectson,ERcancer,Obj
naringenintreatmentgroup,expressionof,ERÎ±66,Obj
treatment,markedlysuppressed,cellmigration,Obj
investigated,combinatorialeffectson,ERcancer,Obj
combinedtreatment,suppressing,transcriptionofcellcycleregulationproteins,Obj
naringenin,inhibit,cellgrowthatconcentrations,Obj
cellproliferation,Takentogether,co-treatmentoftamoxifen,Obj
co-treatment,regulating,expressionofmitochondrialapoptoticproteins,Obj
treatment,suppressing,transcriptionofcellcycleregulationproteins,Obj
naringenin,inhibit,cellgrowth,Obj
treatment,blockedcellcyclein,G2/Mphase,Obj
cellmigration,combinedtreatmentof,tamoxifen,Obj
naringenin,inhibit,cellgrowthofMCF-7cellsathigherconcentrations,Obj
treatment,blocked,cellcycle,Obj
cellproliferation,Taken,co-treatment,Obj
combinedtreatment,markedlysuppressed,cellmigration,Obj
purpose,develop,4Ddigitalbreastphantomincludingtime-varyingcontrastenhancementforsimulationofdedicatedbreastCTperfusionimaging,Obj
3Dphantom,segmentingbreastCTimagefrom,patient,Obj
randomdistribution,isused,varyonvoxel-basis,Obj
modality,couldprovide,informationofbreastresultingindetectiondiagnosisofbreastcancer,Obj
breastlesionmodel,beaddedto,phantom,Obj
tumormodels,Moreovershow,enhancementdynamics,Obj
characteristics,evaluate,perfusionindifferenttypesofbreastlesions,Obj
3Dphantom,segmenting,breastCTimage,Obj
uniformdistribution,isused,varyonvoxel-basis,Obj
randomdistribution,isused,vary,Obj
time-enhancementcurves,arecomputedfor,voxel,Obj
3Dstaticphantom,segmentingbreastCTimagefrom,patient,Obj
perfusion,isin,differenttypesofbreastlesions,Obj
tumormodels,evaluatedin,work,Obj
3Dphantom,segmentingbreastCTimagefrom,healthypatientintoskinfibroglandulartissueadiposetissue,Obj
distribution,varyon,voxel-basis,Obj
tumormodels,show,differentenhancementdynamics,Obj
modality,couldprovide,functionalinformation,Obj
typical4Dphantom,hasdimensionsAs,example,Obj
distribution,varyperfusionparameterson,voxel-basis,Obj
uniformrandomdistribution,varyperfusionparameterson,voxel-basis,Obj
uniformrandomdistribution,vary,perfusionparameters,Obj
proposeddigitalphantom,canmodelbreasttissueperfusionduring,4DbreastCTimageacquisition,Obj
typical4D,hasdimensionsAs,example,Obj
modality,couldprovide,functionalinformationofbreastresultingindetectiondiagnosisofbreastcancerwithbreastCT.,Obj
modality,couldprovide,informationofbreastresulting,Obj
3Dstaticphantom,segmentingbreastCTimagefrom,healthypatientintoskinfibroglandulartissueadiposetissue,Obj
arterialsources,supplying,breast,Obj
detectiondiagnosis,iswith,breastCT.,Obj
distribution,isused,vary,Obj
uniformdistribution,varyon,voxel-basis,Obj
Results,show,expectedenhancementoftissuesconsistentwithgiveninputparameters,Obj
proposeddigitalphantom,canmodel,breasttissueperfusion,Obj
randomdistribution,varyperfusionparameterson,voxel-basis,Obj
distribution,isused,varyonvoxel-basis,Obj
curves,arecomputedfor,voxel,Obj
distribution,vary,perfusionparameters,Obj
modality,couldprovide,informationofbreast,Obj
modality,couldprovide,informationofbreastresultingindetectiondiagnosiswithbreastCT.,Obj
correspondingcurves,arecomputedfor,voxel,Obj
proposedphantom,canmodel,breasttissueperfusion,Obj
uniformdistribution,vary,perfusionparameters,Obj
correspondingtime-enhancementcurves,arecomputedfor,voxel,Obj
modality,couldprovide,informationofbreastresultingindetectiondiagnosis,Obj
phantom,canmodel,breasttissueperfusion,Obj
randomdistribution,varyon,voxel-basis,Obj
exponential,dependson,perfusionparametersassociatedwithtissuevoxel,Obj
modality,couldprovide,informationofbreastresultingindetectiondiagnosisofbreastcancerwithbreastCT.,Obj
tumormodels,show,enhancementdynamics,Obj
digitalphantom,canmodel,breasttissueperfusion,Obj
modality,couldprovide,information,Obj
curves,arecalculatedby,convolutionbetweenarterialinputfunction,Obj
activities,antioxidantfree-radicalscavengingagainst,celllines,Obj
percentcytotoxicity,increasesteadilywith,increasingOPAEconcentration,Obj
aqueousOrthosiphonpallidusextract,showed,potentactivityinin-vitromodels,Obj
objective,investigate,antioxidantfree-radicalscavengingagainsthumanbreast-cancercelllines,Obj
Orthosiphonpallidusextract,showed,activityinin-vitromodels,Obj
percentcytotoxicity,increasewith,increasingOPAEconcentrationupto240g/mL,Obj
Orthosiphonpallidusextract,showed,potentactivityinin-vitromodels,Obj
activities,antioxidantfree-radicalscavengingagainst,humancelllines,Obj
anticanceractivities,antioxidantfree-radicalscavengingagainst,humanbreast-cancercelllines,Obj
anticanceractivities,scavengingagainst,humancelllines,Obj
percentcytotoxicity,increasewith,increasingOPAEconcentration,Obj
Orthosiphonpallidusextract,showed,potentactivity,Obj
percentcytotoxicity,increasesteadilywith,OPAEconcentrationupto240g/mL,Obj
Orthosiphonpallidusextract,showed,activity,Obj
percentcytotoxicity,increasewith,OPAEconcentration,Obj
objective,investigate,anticanceractivitiesofO.pallidus,Obj
percentcytotoxicity,increasewith,OPAEconcentrationupto240g/mL,Obj
objective,investigate,free-radicalscavengingagainsthumanbreast-cancercelllines,Obj
activities,antioxidantfree-radicalscavengingagainst,humanbreast-cancercelllines,Obj
total,reducing,poweractivities,Obj
potentactivity,isin,in-vitromodels,Obj
objective,investigate,free-radicalscavenging,Obj
percentcytotoxicity,increasesteadilywith,increasingOPAEconcentrationupto240g/mL,Obj
Orthosiphonpallidusextract,showed,activityinmodels,Obj
percentcytotoxicity,increasesteadilywith,OPAEconcentration,Obj
percentcytotoxicity,wasfoundFor,celllines,Obj
Orthosiphonpallidusextract,showed,potentactivityinmodels,Obj
retrospectivestudy,included,womenwithBCstreatedfrom2008to2017,Obj
retrospectivestudy,included,womenwithHER2-positiveBCstreatedwithtrastuzumabfrom2008to2017,Obj
196patients,isin,groupAB,Obj
seriousdamage,selecting,nABregimen,Obj
retrospectivestudy,included,women,Obj
retrospectivestudy,included,womenwithHER2-positiveBCstreatedwithtrastuzumab,Obj
patients,weredividedinto,twogroupsincluding196patients,Obj
anthracycline-basedadjuvanttherapies,isin,humanepidermalgrowthfactorreceptor2,Obj
seriousdamage,Thereforeselecting,nABregimen,Obj
study,included,women,Obj
women,iswith,HER2-positiveBCstreatedfrom2008to2017,Obj
damage,Thereforeselecting,nABregimen,Obj
damage,selecting,nABregimen,Obj
clinicians,build,prognosisdiscussioncommunicationskills,Obj
patients,diagnosedwith,advancedbreastcancer,Obj
patients,iswith,advancedbreastcancer,Obj
Mostpatients,found,appointment,Obj
clinicians,found,interventioneasy,Obj
analysis,assess,interventionfeasibility,Obj
Patientself-reports,werecomparedacross,intervention,Obj
Mostpatients,found,T-PATappointment,Obj
Femalepatients,diagnosedwith,advancedbreastcancer,Obj
patients,diagnosedwith,breastcancer,Obj
T-PATparticipants,hold,realisticbeliefsaboutdiseasecurability,Obj
effects,feasibilityof,plannedprognosisdiscussion,Obj
patients,found,appointment,Obj
findings,indicate,utilizationofacidforbreastcancertherapy,Obj
compound,reduces,aldehydedehydrogenase,Obj
findings,indicate,utilizationforbreastcancertherapyviadisruption,Obj
repeatedpreparations,ledto,isolationofonecompound,Obj
compound,reduces,CD44high/CD24lowsubpopulation,Obj
compound,inhibitsbreastcancercellproliferationin,dose-dependentmanner,Obj
TargetingbreastCSCs,isparadigmfor,cancerprevention,Obj
repeatedpreparations,ledto,isolation,Obj
aldehydedehydrogenase,expressing,expressionofself-renewal-relatedgenes,Obj
chromatographicpreparations,ledto,isolation,Obj
compound,reduces,ALDH,Obj
repeatedchromatographicpreparations,ledto,isolation,Obj
TargetingbreastCSCs,isnewparadigmfor,cancerprevention,Obj
findings,indicate,novelutilizationof3-O-p-coumaroyltormenticacidforbreastcancertherapyviadisruption,Obj
chromatographicpreparations,ledto,isolationofonecompound,Obj
preparations,ledto,isolationofonecompound,Obj
preparations,ledto,isolation,Obj
repeatedchromatographicpreparations,ledto,isolationofonecompound,Obj
compound,inhibits,breastcancercellproliferation,Obj
TargetingbreastCSCs,iswith,phytochemicals,Obj
Patients,presenting,early-stagebreastcancer,Obj
G1,wasAt,endofRTtreatmentskintoxicity,Obj
G1,wasAt,end,Obj
patients,receivedVMAT-SIBtechniquein,15fractions,Obj
HypofractionatedVMAT-SIB,isin,patients,Obj
outcomes,review,associationofchemotherapywithboost,Obj
cosmeticoutcomes,review,associationwithboost,Obj
VMAT-SIB,toleratedin,termsofacute,Obj
outcomes,werealsoassessedas,excellent/good,Obj
cosmeticoutcomes,review,associationofchemotherapy,Obj
patients,receivedVMAT-SIBtechniqueto,wholebreast,Obj
Cosmeticoutcomes,werealsoassessedas,excellent/good,Obj
outcomes,wereassessedas,excellent/good,Obj
Ourdata,confirmed,resultsofotherstudiespublishedonassociationofhypofractionation,Obj
G1,wasin,51.1%ofpatientsG2,Obj
outcomes,review,associationwithboost,Obj
Cosmeticoutcomes,wereassessedas,excellent/good,Obj
HypofractionatedVMAT-SIB,welltoleratedin,terms,Obj
patients,receivedVMAT-SIBtechniquein,15fractionsfortotaldose,Obj
HypofractionatedVMAT-SIB,welltoleratedin,termsofacute,Obj
outcomes,review,associationofchemotherapy,Obj
Patients,presenting,breastcancer,Obj
HypofractionatedVMAT-SIB,toleratedin,termsofacute,Obj
Patients,wereenrolledin,phaseIItrial,Obj
patients,received,VMAT-SIBtechnique,Obj
patients,receivedVMAT-SIBtechniqueto,breast,Obj
cosmeticoutcomes,review,associationofchemotherapywithboost,Obj
patients,receivedVMAT-SIBtechniquein,15fractionsfordose,Obj
assays,areprognosticfor,recurrenceselectiontools,Obj
Higherexpression,wasassociatedwith,recurrenceriskbeyond5years,Obj
clinicopathologicalparameters,areprognosticfor,laterecurrenceselectiontools,Obj
patients,iswith,ER-positive/humanepidermalgrowthfactorreceptor2-negativebreastcancer,Obj
clinicopathologicalparameters,areprognosticfor,recurrenceselectiontools,Obj
effect,disappearedafter,treatmentcessation,Obj
Enhancedunderstanding,couldoptimize,patientselection,Obj
Higherexpression,wasassociatedwith,recurrenceriskbeyond5yearsafterdiagnosis,Obj
severalparameters,areprognosticfor,laterecurrenceselectiontools,Obj
severalclinicopathologicalparameters,areprognosticfor,laterecurrenceselectiontools,Obj
Higherexpression,wasassociatedwith,recurrencerisk,Obj
assays,areprognosticfor,laterecurrenceselectiontools,Obj
laterecurrences,iswith,highexpressionofestrogen-responsivegenes,Obj
intervention,mightreduce,recurrences,Obj
severalparameters,areprognosticfor,recurrenceselectiontools,Obj
severalclinicopathologicalparameters,areprognosticfor,recurrenceselectiontools,Obj
expression,wasassociatedwith,highrecurrenceriskbeyond5yearsafterdiagnosis,Obj
expression,wasassociatedwith,highrecurrenceriskbeyond5years,Obj
expression,wasassociatedwith,recurrenceriskbeyond5years,Obj
laterecurrencerisk,Extending,5yearsoftamoxifentherapywith5yearsoftamoxifen,Obj
recurrenceselectiontools,predicting,benefit,Obj
showing,highexpressionof,genes,Obj
laterecurrenceselectiontools,predicting,benefit,Obj
parameters,areprognosticfor,recurrenceselectiontools,Obj
effect,disappeared,5yearsofendocrinetherapyreduced,Obj
parameters,areprognosticfor,laterecurrenceselectiontools,Obj
intervention,mightreduce,laterecurrencesinpatientswithtumors,Obj
predicting,benefitfrom,extendedendocrinetherapy,Obj
Long-termintervention,mightreduce,laterecurrencesinpatients,Obj
Extendedendocrinetherapy,canreduce,recurrencesoccurring,Obj
recurrenceselectiontools,predicting,benefitfromextendedendocrinetherapy,Obj
multigeneassays,areprognosticfor,laterecurrenceselectiontools,Obj
intervention,mightreduce,recurrencesinpatients,Obj
Enhancedunderstanding,couldoptimizepatientselectionin,setting,Obj
showing,expressionof,estrogen-responsivegenes,Obj
showing,expressionof,genes,Obj
Higherexpression,wasassociatedwith,highrecurrencerisk,Obj
intervention,mightreduce,recurrencesinpatientswithtumors,Obj
diagnosis,isin,estrogenreceptor,Obj
Long-termintervention,mightreduce,recurrencesinpatientswithtumors,Obj
Extendedendocrinetherapy,canreduce,recurrences,Obj
Extendedtherapy,canreduce,recurrences,Obj
Long-termintervention,mightreduce,recurrencesinpatients,Obj
laterecurrenceselectiontools,predicting,benefitfromextendedendocrinetherapy,Obj
EnrichmentAnalysis,wasappliedon,genes,Obj
understanding,couldoptimizepatientselectionin,setting,Obj
Higherexpression,wasassociatedwith,highrecurrenceriskbeyond5years,Obj
expression,wasassociatedwith,highrecurrencerisk,Obj
laterecurrences,isin,patientswithtumorsshowing,Obj
Long-termintervention,mightreduce,laterecurrencesinpatientswithtumors,Obj
Long-termintervention,mightreduce,recurrences,Obj
intervention,mightreduce,laterecurrencesinpatients,Obj
intervention,mightreduce,laterecurrences,Obj
expression,wasassociatedwith,recurrencerisk,Obj
Long-termintervention,mightreduce,laterecurrences,Obj
Long-termintervention,isin,pathway,Obj
recurrenceselectiontools,predicting,benefitfromendocrinetherapy,Obj
expression,wasassociatedwith,recurrenceriskbeyond5yearsafterdiagnosis,Obj
Higherexpression,wasassociatedwith,highrecurrenceriskbeyond5yearsafterdiagnosis,Obj
therapy,canreduce,recurrences,Obj
estrogenreceptor,indiagnosisis,laterecurrences,Obj
Extendedtherapy,canreduce,recurrencesoccurring,Obj
patients,iswith,tumorsshowing,Obj
multigeneassays,areprognosticfor,recurrenceselectiontools,Obj
showing,highexpressionof,estrogen-responsivegenes,Obj
therapy,canreduce,recurrencesoccurring,Obj
laterecurrenceselectiontools,predicting,benefitfromendocrinetherapy,Obj
Ongoingresearch,isanticipated,continue,Obj
importantgrowthpathway,isin,HRpositivebreastcancerPI3Kinhibitors,Obj
data,remainsfor,sequencing,Obj
therapies,oftendelay,initiationarelacking,Obj
mTORinhibitoreverolimus,addedto,ET,Obj
Analysis,hasledto,developmentofgenerationoftargetedtherapiesforadvancedbreastcancer,Obj
Analysis,hasledto,developmentofnewgenerationoftargetedtherapiesforadvancedbreastcancer,Obj
mTORinhibitoreverolimus,significantlyimproves,progressionfreesurvival,Obj
Ongoingresearch,evaluating,potentialbiomarkersofresistance,Obj
Ongoingresearch,evaluating,mechanisms,Obj
majority,arein,patientswithhormonereceptor,Obj
therapies,oftendelay,initiationofchemotherapylongtermoverallsurvivaldataarelacking,Obj
research,isanticipated,continue,Obj
research,evaluating,potentialbiomarkersofresistance,Obj
anti-estrogentherapy,iswith,selectiveestrogenreceptormodulators,Obj
data,remains,unclear,Obj
majority,arein,patients,Obj
therapy,remains,backboneincases,Obj
patients,iswith,hormonereceptor,Obj
agents,remainsfor,idealstrategy,Obj
managementchallenges,isin,treatmentofadvancedHRpositiveHER2negativebreastcancerhighlighting,Obj
therapies,delay,initiationofchemotherapytermsurvivaldataarelacking,Obj
PI3K/AKT/mTORpathway,isknown,growthpathway,Obj
selectiveestrogenreceptormodulators,iswith,cyclindependentkinase,Obj
therapies,oftendelay,initiationofchemotherapylongtermsurvivaldataarelacking,Obj
therapies,delay,initiationofchemotherapylongtermoverallsurvivaldataarelacking,Obj
mTORinhibitoreverolimus,improves,progressionfreesurvival,Obj
Ongoingresearch,evaluating,potentialbiomarkers,Obj
data,remainsfor,strategy,Obj
supportivecare,allowing,lesstoxicity,Obj
mTORinhibitoreverolimus,improved,supportivecareallowing,Obj
mTORinhibitoreverolimus,improves,progressionsurvival,Obj
therapy,remains,backboneoftreatment,Obj
data,remainsfor,idealstrategy,Obj
therapies,delay,initiationarelacking,Obj
patients,iswith,HRpositivemetastaticbreastcancer,Obj
therapies,improve,outcomes,Obj
mTORinhibitoreverolimus,improved,supportivecare,Obj
therapy,remains,backboneoftreatmentincases,Obj
PI3K/AKT/mTORpathway,isknown,growthpathwayinHRpositivebreastcancerPI3Kinhibitors,Obj
therapy,backboneof,treatment,Obj
deaths,majorityofare,patientswithhormonereceptor,Obj
research,evaluating,mechanisms,Obj
therapies,isin,clinic,Obj
mTORinhibitoreverolimus,significantlyimproves,progressionsurvival,Obj
research,evaluating,potentialbiomarkers,Obj
therapies,oftendelay,initiationofchemotherapytermsurvivaldataarelacking,Obj
treatment,canlose,effectiveness,Obj
Sexualfunction,waschangedin,womenwithbreastcancer,Obj
problems,included,dysfunctionalexcitement,Obj
participants,ofageis,Â±standarddeviationSD,Obj
Sexualfunction,waschangedin,women,Obj
dysfunctions,weredueto,penetrationpain,Obj
mainproblems,included,penetrationpaindesirelubrication,Obj
participants,averageageofwas,46.34Â±8.28years,Obj
averagetime,sufferingfrom,cancer,Obj
primarysexualdysfunctions,weredueto,penetrationpain,Obj
instruments,werequestionnaireon,Women'sSexualFunction,Obj
study,included,514womenwithbreastcancer,Obj
mainproblems,included,dysfunctionalexcitement,Obj
changes,isin,sexuality,Obj
circumstances,influencefunctionwith,breastcancer,Obj
514women,iswith,breastcancer,Obj
mainproblems,included,excitement,Obj
study,included,514women,Obj
events,areresponsiblefor,increaseinERÎ±proteinlevels,Obj
ERÎ±polyubiquitinationselectiveestrogenreceptordegraders,resultingin,ERÎ±degradation,Obj
regulator,islinked,relatedtoendocrinetherapyresistance,Obj
transcriptionalregulator,islinkedto,developmentoftumors,Obj
transcriptionalregulator,islinked,related,Obj
posttranslationalmodificationsinteractions,iswith,coregulatorsofspecificproteincomplexes,Obj
related,alsofunctionas,coactivators,Obj
extranuclearactivity,isrelatedto,endocrinetherapyresistance,Obj
maykeyfactor,isin,progressionofbreastcancer,Obj
regulator,islinked,related,Obj
activity,isrelatedto,endocrinetherapyresistance,Obj
polyubiquitination,Moreoverisrelatedto,ERÎ±transcriptioncycle,Obj
related,alsofunctionas,coactivatorsforERÎ±,Obj
transcriptionalregulator,islinkedto,developmentofmammarytumors,Obj
related,functionas,coactivators,Obj
ERÎ±polyubiquitinationestrogenreceptordegraders,resultingvia,ubiquitinproteasomesystem,Obj
polyubiquitination,isrelatedto,ERÎ±transcriptioncycle,Obj
increase,isin,ERÎ±proteinlevels,Obj
transcriptionalregulator,islinked,relatedtotherapyresistance,Obj
regulator,islinkedto,development,Obj
related,functionas,coactivatorsforERÎ±,Obj
regulator,islinked,relatedtotherapyresistance,Obj
ERÎ±polyubiquitinationestrogenreceptordegraders,resultingin,ERÎ±degradation,Obj
regulator,islinkedto,developmentofmammarytumors,Obj
ERÎ±polyubiquitination,isinducedby,estradiolhormone,Obj
transcriptionalregulator,islinkedto,development,Obj
extranuclearactivity,isrelatedto,therapyresistance,Obj
ERÎ±polyubiquitinationselectiveestrogenreceptordegraders,resultingvia,ubiquitinproteasomesystem,Obj
transcriptionalregulator,islinked,relatedtoendocrinetherapyresistance,Obj
specificproteincomplexes,iswith,ERÎ±,Obj
aim,assess,OBCS,Obj
Itspotentialpracticalapplications,merit,investigation,Obj
aim,assess,ObjectiveBreastCosmesisScale,Obj
patients,received,adjuvantpartialbreastirradiation,Obj
Itspotentialpracticalapplications,merit,furtherinvestigation,Obj
patients,received,breastirradiation,Obj
Onephotograph,beforeandanotherwastakenfor,patient,Obj
patients,received,partialbreastirradiation,Obj
Itspotentialapplications,merit,furtherinvestigationinfuturestudies,Obj
Itspotentialpracticalapplications,merit,investigationinfuturestudies,Obj
Onephotograph,record,changes,Obj
Theirtreatment-relatedcosmeticchanges,wererecordedon,nonstandardizedphotographs,Obj
patients,hadundergone,breast-conservingsurgery,Obj
patients,received,adjuvantbreastirradiation,Obj
Itspotentialapplications,merit,furtherinvestigation,Obj
patients,received,acceleratedpartialbreastirradiation,Obj
Onephotograph,beforewastakenfor,patient,Obj
patients,received,adjuvantacceleratedbreastirradiation,Obj
changes,isin,breastcosmesis,Obj
Itspotentialapplications,merit,investigation,Obj
Agreement,washighbetween,trainees,Obj
patients,hadundergone,surgery,Obj
Onephotograph,record,changesinbreastcosmesis,Obj
correlationcoefficient,rangedbefore,treatment,Obj
intraclasscorrelationcoefficient,rangedbefore,treatment,Obj
Itspotentialpracticalapplications,merit,furtherinvestigationinfuturestudies,Obj
patients,received,adjuvantacceleratedpartialbreastirradiation,Obj
partialbreastirradiation,using,interstitialfractionatedhigh-dose-ratebrachytherapy,Obj
acceleratedpartialbreastirradiation,using,brachytherapy,Obj
furtherinvestigation,isin,futurestudies,Obj
S961,downregulatedIRswith,nanomolardose,Obj
IRantagonistS961,showed,distinctantagonism,Obj
effect,wasevaluatedby,MTT,Obj
IRmRNAexpressionlevels,weresignificantlydownregulatedin,continuedpresence,Obj
expression,regulates,aspectsofmalignantphenotype,Obj
expression,regulates,severalaspects,Obj
study,investigate,pivotalroleofIRantagonistS961,Obj
S961,blockedexpressionin,evenpresenceofinsulin,Obj
study,investigate,roleofIRantagonistS961,Obj
study,investigate,roleofIRantagonistS961onIRsignallinginMCF-7MDA-MB-231,Obj
IRmRNAexpressionlevels,weredownregulatedin,presenceofS961,Obj
S961,inhibited,proliferationinbreasttumourcells,Obj
study,investigate,roleonIRsignallinginMCF-7MDA-MB-231,Obj
study,investigate,roleonIRsignalling,Obj
study,investigate,pivotalroleofIRantagonistS961onIRsignalling,Obj
breastcancercells,predominantlyexpressed,IR-Aisoform,Obj
mRNAexpression,wasmeasuredin,breastcarcinomacells,Obj
upregulatedexpression,regulates,severalaspectsofmalignantphenotypeincludingcellproliferation,Obj
breastcancercells,expressed,IR-Aisoform,Obj
S961,blocked,expressionofIRs,Obj
study,investigate,roleofIRantagonistS961onIRsignalling,Obj
IRmRNAexpressionlevels,weredownregulatedin,continuedpresenceofS961,Obj
aspects,expressionin,breastcancerpathogenesis,Obj
expression,regulates,severalaspectsofmalignantphenotypeincludingcellproliferation,Obj
study,investigate,pivotalroleonIRsignalling,Obj
severalaspects,expressionin,breastcancerpathogenesis,Obj
severalaspects,upregulatedexpressionof,IRs,Obj
S961,alsoinhibited,cellularproliferationinbreasttumourcells,Obj
breastcancercells,showed,proliferationowing,Obj
expression,regulates,severalaspectsofmalignantphenotype,Obj
breastcancercells,showed,growth,Obj
mRNAexpression,using,quantitativePCR,Obj
IRmRNAexpressionlevels,weresignificantlydownregulatedin,presenceofS961,Obj
expression,regulates,aspectsofphenotypeincludingcellproliferation,Obj
proliferation,isin,breasttumourcells,Obj
aspects,upregulatedexpressionof,IRs,Obj
breastcancercells,showedgrowthto,IRoverexpression,Obj
IRmRNAexpressionlevels,weresignificantlydownregulatedin,continuedpresenceofS961,Obj
IRantagonistS961,showed,antagonism,Obj
S961,efficientlyblocked,expressionofIRs,Obj
S961,downregulated,IRs,Obj
expression,regulates,severalaspectsofphenotypeincludingcellproliferation,Obj
study,investigate,pivotalroleonIRsignallinginMCF-7MDA-MB-231,Obj
upregulatedexpression,isin,breastcancerpathogenesis,Obj
breastcancercells,showed,extensivegrowth,Obj
expression,regulates,aspectsofmalignantphenotypeincludingcellproliferation,Obj
study,investigate,pivotalroleofIRantagonistS961onIRsignallinginMCF-7MDA-MB-231,Obj
IRmRNAexpressionlevels,weresignificantlydownregulatedin,presence,Obj
S961,inhibited,cellularproliferationinbreasttumourcells,Obj
expression,regulates,severalaspectsofphenotype,Obj
IRsignalling,isin,MCF-7MDA-MB-231,Obj
IRmRNAexpressionlevels,weredownregulatedin,continuedpresence,Obj
breastcancercells,showedproliferationowingto,IRoverexpression,Obj
ImmediateVerbalMemoryIndex,wassignificantlyhigherin,study2,Obj
breastradiotherapy,wasrestoredafter,approximately3years,Obj
mechanisms,underlying,decline,Obj
association,using,Pearson'scorrelationcoefficient,Obj
mechanisms,underlying,cognitivedecline,Obj
changes,isin,WMS-Rindicesbetweentwostudies,Obj
changes,isin,plasmaIL-6levels,Obj
Memorydecline,isin,breastcancerpatients,Obj
mechanisms,remains,unclear,Obj
adjuvantbreastradiotherapy,isin,breastconservationtherapy,Obj
TheDelayed,wassignificantlyhigherin,study2,Obj
TheDelayed,washigherin,study2,Obj
breastradiotherapy,soonwasrestoredafter,approximately3years,Obj
ImmediateVerbalMemoryIndex,washigherin,study2,Obj
threevisualrepresentations,using,threedifferentmetricsofmortality,Obj
TAMs/CXCL1,promotesbreastcancermetastasisvia,NF-ÎºB/SOX4activation,Obj
epithelial-mesenchymaltransition,isin,mouse,Obj
CXCL1silencing,resultsin,reductioninbreastcancergrowth,Obj
therapeutictargets,Howeverarestillrequiredfor,investigation,Obj
significantreduction,isin,breastcancergrowth,Obj
therapeutictargets,Howeverarerequiredfor,investigation,Obj
QPCRscreening,validatedSOX4as,responsivegene,Obj
QPCRscreening,validatedSOX4as,highestresponsivegene,Obj
QPCRscreening,furthervalidatedSOX4following,CXCL1administration,Obj
targets,Howeverarestillrequiredfor,furtherinvestigation,Obj
targets,arerequiredfor,investigation,Obj
CXCL1silencing,resultsin,reduction,Obj
QPCRscreening,furthervalidatedSOX4as,highestresponsivegene,Obj
therapeutictargets,existingin,loopTAMs,Obj
highCXCL1expression,iscorrelatedwith,breastcancerlymphnodemetastasis,Obj
TAMs/CXCL1,promotes,breastcancermetastasis,Obj
QPCRscreening,validatedSOX4following,CXCL1administration,Obj
targets,arestillrequiredfor,investigation,Obj
QPCRscreening,validatedSOX4as,highestgene,Obj
therapeutictargets,arerequiredfor,investigation,Obj
QPCRscreening,furthervalidatedSOX4as,gene,Obj
targets,existingin,loop,Obj
targets,Howeverarestillrequiredfor,investigation,Obj
CXCL1silencing,resultsin,significantreductioninbreastcancergrowth,Obj
targets,Howeverarerequiredfor,investigation,Obj
targets,arerequiredfor,furtherinvestigation,Obj
CXCL1,activates,itstranscription,Obj
therapeutictargets,arerequiredfor,furtherinvestigation,Obj
targets,Howeverarerequiredfor,furtherinvestigation,Obj
CXCL1,bindsto,SOX4promoter,Obj
therapeutictargets,Howeverarestillrequiredfor,furtherinvestigation,Obj
QPCRscreening,furthervalidatedSOX4as,responsivegene,Obj
highCXCL1expression,issignificantlycorrelatedwith,breastcancerlymphnodemetastasis,Obj
therapeutictargets,arestillrequiredfor,furtherinvestigation,Obj
targets,arestillrequiredfor,furtherinvestigation,Obj
CXCL1silencing,isin,TAMs,Obj
targets,existingin,loopTAMs,Obj
CXCL1expression,iscorrelatedwith,breastcancerlymphnodemetastasis,Obj
QPCRscreening,furthervalidatedSOX4as,highestgene,Obj
CXCL1expression,issignificantlycorrelatedwith,breastcancerlymphnodemetastasis,Obj
therapeutictargets,arestillrequiredfor,investigation,Obj
3patients,received,Level0doses,Obj
4patients,received,Level1doses,Obj
Level1group,ofpatientis,Grade3oralmucositis,Obj
patients,iswith,advancedrecurrentbreastcancer,Obj
otherpatients,received,Level1doses,Obj
doses,wereescalatedfor,GEM,Obj
efficacy,isin,combinationwithotherchemotherapeuticagents,Obj
patients,received,Level0doses,Obj
dose,wasfoundin,Grade3oralmucositis,Obj
doses,wereescalatedfor,Level1,Obj
ERI,ofdosesis,Level0,Obj
combinationtherapy,iswith,ERI,Obj
dose,wasfoundin,only1patientofLevel1group,Obj
Japanesepatients,iswith,metastaticbreastcancer,Obj
tolerability,iswith,ERI,Obj
Iclinicalstudy,isin,Japanesepatientswithmetastaticbreastcancer,Obj
patients,received,Level1doses,Obj
type,iswith,closedloopstructure,Obj
Breastcancer,causeof,cancer-relateddeath,Obj